CD8A and neoplasm: To bypass the isolation and expansion of autologous tumour-reactive CD8+ T cells, the use of bulk T cells from the peripheral blood for CAR T-cell manufacturing has been applied, and has revolutionised adoptive cell transfer in oncology.50